Literature DB >> 16804960

Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.

Kai-Yu Ji1, Fu-Lian Hu.   

Abstract

According to a meta-analysis, H pylori and non-steroidal anti-inflammatory drugs (NSAID) independently and significantly increase the risk of gastroduodenal ulcer and ulcer bleeding. Their coincidence is frequent, demonstration of a possible relationship and consequent attitude is of important implications. But unfortunately, no consensus has been approved in the past years and their interactions are still controversial. H pylori and NSAID are known to share a number of pathogenic mechanisms, but there is no evidence for the significant synergic action between these two risk factors. Their relationship is independent, additive, synergistic or antagonistic without considering the influence of other factors because studies on this subject are different in almost all aspects of their methodology, including the definition of a NSAID user as well as the types, doses, duration and their indications for NSAID use, as well as their end-points, definition of dyspepsia and regimes used for eradication of H pylori. These might contribute to the conflicting results and opinions. H pylori infection in humans does not act synergistically with NSAID on ulcer healing, and there is no need to eradicate it. This notion is supported by the finding that the eradication of H pylori does not affect NSAID-induced gastropathy treated with omeprazole and that H pylori infection induces a strong cyclooxygenase-2 (COX-2) expression resulting in excessive biosynthesis of gastroprotective prostaglandin which in turn counteracts NSAID-induced gastropathy and heals the existing ulcer. Other investigators claimed that H pylori infection acts synergistically with NSAID on ulcer development, and H pylori should be eradicated, particularly at the start of long-term NSAID therapy. Eradication of H pylori prior to NSAID treatment does not appear to accelerate ulcer healing or to prevent recurrent ulcers in NSAID users. However, some recommendations can be drawn from the results of clinical trails.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804960      PMCID: PMC4087923          DOI: 10.3748/wjg.v12.i24.3789

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer.

Authors:  Chun-Ying Wu; Ming-Sing Wu; Chien-Jen Chen; Mu-Chun Li; Jaw-Town Lin; Gran-Hum Chen
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

Review 2.  [Should Helicobacter pylori infection be tested and eradicated in patients treated or about to be treated with aspirin or nonsteroidal anti-inflammatory drugs?].

Authors:  Gérard Thiéfin
Journal:  Gastroenterol Clin Biol       Date:  2003-03

3.  Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.

Authors:  C J Hawkey; J Naesdal; I Wilson; G Långström; A J Swannell; R A Peacock; N D Yeomans
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 4.  [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].

Authors:  S Limmer; T H Ittel; H Wietholtz
Journal:  Z Gastroenterol       Date:  2003-08       Impact factor: 2.000

Review 5.  Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing.

Authors:  R H Hunt; F Bazzoli
Journal:  Aliment Pharmacol Ther       Date:  2004-02       Impact factor: 8.171

6.  Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study.

Authors:  Abdullah Okan; Ethem Tankurt; Belgin U Aslan; Hale Akpinar; Ilkay Simsek; Omur Gonen
Journal:  J Gastroenterol Hepatol       Date:  2003-01       Impact factor: 4.029

7.  Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.

Authors:  Donald R Campbell; Marian M Haber; Eric Sheldon; Cyndy Collis; Nancy Lukasik; Bidan Huang; Jay L Goldstein
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

Review 8.  [Treatment of NSAIDs related dyspepsia].

Authors:  Frank Zerbib
Journal:  Gastroenterol Clin Biol       Date:  2004-04

9.  Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Authors:  Francis K L Chan; Lawrence C T Hung; Bing Y Suen; Justin C Y Wu; Kenneth C Lee; Vincent K S Leung; Aric J Hui; Ka F To; Wai K Leung; Vincent W S Wong; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

10.  Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study.

Authors:  F-H Ng; B C-Y Wong; S-Y Wong; W-H Chen; C-M Chang
Journal:  Aliment Pharmacol Ther       Date:  2004-02-01       Impact factor: 8.171

View more
  8 in total

1.  Analysis of immune responses against H pylori in rabbits.

Authors:  Khademul Islam; Ibrahim Khalil; Chowdhury Rafiqul Ahsan; Mahmuda Yasmin; Jamalun Nessa
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 2.  Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly.

Authors:  Angel Lanas; Angel Ferrandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 3.  Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients.

Authors:  Corrado Blandizzi; Marco Tuccori; Rocchina Colucci; Giovanni Gori; Matteo Fornai; Luca Antonioli; Narcisa Ghisu; Mario Del Tacca
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  The effect of non-steroidal anti-inflammatory drugs and Helicobacter pylori infection on the gastric mucosa in children with upper gastrointestinal bleeding.

Authors:  Samir Boukthir; Sonia M Mazigh; Nicolas Kalach; Nicolas Kaach; Olfa Bouyahya; Azza Sammoud
Journal:  Pediatr Surg Int       Date:  2009-10-13       Impact factor: 1.827

5.  Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.

Authors:  Kentaro Sugano; Yoshikazu Kinoshita; Hiroto Miwa; Tsutomu Takeuchi
Journal:  BMC Gastroenterol       Date:  2013-03-26       Impact factor: 3.067

6.  GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.

Authors:  Byron Cryer; Chunming Li; Lee S Simon; Gurkirpal Singh; Martin J Stillman; Manuela F Berger
Journal:  Am J Gastroenterol       Date:  2013-02-12       Impact factor: 10.864

7.  Treatment and chemoprevention of NSAID-associated gastrointestinal complications.

Authors:  Edward J Frech; Mae F Go
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

8.  Combination of Xuesaitong and Aspirin Based on the Antiplatelet Effect and Gastrointestinal Injury: Study Protocol for a Randomized Controlled Noninferiority Trial.

Authors:  Bao-Chen Zhu; Chun-Miao Xue; Rui Lang; Wei-Liang Weng; Xu-Jie Wang; Zhen-Zhen Lei; Sha-Sha Zhang; Wen-Hua Yang; Wan-Tong Zhang; Guo-Dong Hua
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.